Accelerating Next-Generation Targeted Conjugates: Integrated Discovery Solutions for Dual-Payload ADC Innovation

• Dual-payload ADCs (dpADCs) are emerging as a next-generation oncology modality to overcome drug resistance and enhance therapeutic efficacy through complementary mechanisms of action.
• Successful dpADC development requires integrated expertise in antibody engineering, payload selection, linker design, precise conjugation, analytical characterization, and pharmacological evaluation to address increasing molecular complexity.
• WuXi XDC’s integrated discovery platform, proprietary WuXiDARx® conjugation technologies, and innovative X-LinC™ linker platform enable flexible dpADC design, controlled payload ratios, improved conjugate stability, and accelerated progression from target selection to fully characterized lead candidates.

Speakers:

Gang Yin

Head of Discovery Service

WuXi XDC